Intervention not reported
Adverse events: a. mild hypoglycaemia (episodes per participant)
1 finding from 1 review
Adverse events# (e.g. choking or vomiting at time of administration) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in adverse events# (e.g. choking or vomiting at time of administration) compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events ( · Patients between three and 12 years old with clinical and EEG diagnosis of BECTS
The intervention showed no clear difference in proportion of patients who discontinued treatment due to adverse… (low certainty).
1 finding from 1 review
Serious adverse events (≥ 1 symptom related to study drug or not) (Range of · infants
IPV‐OPV showed no clear difference in serious adverse events (≥ 1 symptom related to study drug or not)… compared with IPV (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: a. mild to moderate hypoglycaemia (episodes per participant)
1 finding from 1 review
Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (28 weeks trial period) · Patients between five and 15 years old with a diagnosis of BECTS
The intervention showed no clear difference in proportion of patients who discontinued treatment due to adverse… (low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (96 weeks trial period) · Patients with a clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who discontinued treatment due to adverse… (very low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (over 6 months trial period) · Patients between three and 10 years old with a diagnosis of BECTS
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Fexofenadine 120 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (1‐week intervention) (moderate certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema
Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Cetirizine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found